Compare PAA & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAA | RDY |
|---|---|---|
| Founded | 1981 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 11.6B |
| IPO Year | N/A | N/A |
| Metric | PAA | RDY |
|---|---|---|
| Price | $17.72 | $14.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $20.44 | $16.90 |
| AVG Volume (30 Days) | ★ 3.0M | 1.2M |
| Earning Date | 02-06-2026 | 01-22-2026 |
| Dividend Yield | ★ 8.66% | 0.50% |
| EPS Growth | 8.03 | ★ 9.95 |
| EPS | ★ 1.21 | 0.79 |
| Revenue | ★ $46,917,000,000.00 | $3,851,623,984.00 |
| Revenue This Year | N/A | $6.16 |
| Revenue Next Year | $3.43 | $2.57 |
| P/E Ratio | ★ $14.46 | $18.09 |
| Revenue Growth | N/A | ★ 14.10 |
| 52 Week Low | $15.58 | $12.26 |
| 52 Week High | $21.00 | $16.17 |
| Indicator | PAA | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 57.14 | 57.62 |
| Support Level | $17.53 | $13.90 |
| Resistance Level | $17.89 | $14.25 |
| Average True Range (ATR) | 0.26 | 0.16 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 50.77 | 95.87 |
Plains All American Pipeline LP through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and barges or railcars. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminalling. It generates the majority of its revenue from the Crude Oil segment.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.